Effects of Vericiguat on the Mitochondrial Function and Clinical Outcomes in CRT Nonresponders Patients - PubMed
4 hours ago
- #CRT nonresponders
- #mitochondrial function
- #vericiguat
- Vericiguat treatment in CRT nonresponders resulted in a significantly higher CRT responder rate (42.9% vs 12.3%) and lower heart failure hospitalizations (11.1% vs 27.5%) at 1 year compared to untreated patients.
- Patients on vericiguat showed improved mitochondrial function, including reduced methoxyisobutylisonitrile washout, enhanced ATP synthesis, and increased sirtuins3-6 expression, along with reduced inflammatory/oxidative stress levels.
- Vericiguat and sacubitril/valsartan were predictors of CRT responder outcomes, while low baseline ATP was associated with increased risk of heart failure hospitalizations.
- The study concluded that vericiguat likely improves clinical outcomes in CRT nonresponders by enhancing mitochondrial function and reducing inflammation/oxidative stress, though larger studies are needed for confirmation.